{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:20:22Z","timestamp":1787678422529,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016259","name":"Viatris Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.thromres.2026.109798","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:10:50Z","timestamp":1786342250000},"page":"109798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and efficacy of fondaparinux in pediatric venous thromboembolism: A retrospective cohort study"],"prefix":"10.1016","volume":"264","author":[{"given":"Guy","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna","family":"Ganapathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Jagtap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Verbist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Haughie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.thromres.2026.109798_bb0005","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.thromres.2026.109798_bb0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"Brand\u00e3o","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2026.109798_bb0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/asheducation-2018.1.399","article-title":"Management of thrombosis in children and neonates: practical use of anticoagulants in children","volume":"2018","author":"Monagle","year":"2018","journal-title":"Hematology. American Society of Hematology. Education Program"},{"issue":"10","key":"10.1016\/j.thromres.2026.109798_bb0020","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/bloodadvances.2024015328","article-title":"American Society of Hematology\/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients","volume":"9","author":"Monagle","year":"2025","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.thromres.2026.109798_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28295","article-title":"FondaKIDS III: a long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children","volume":"67","author":"Shen","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.thromres.2026.109798_bb0030","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/pbc.23011","article-title":"FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age","volume":"57","author":"Young","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.thromres.2026.109798_bb0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.thromres.2014.07.026","article-title":"FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events","volume":"134","author":"Ko","year":"2014","journal-title":"Thromb. Res."},{"issue":"9","key":"10.1016\/j.thromres.2026.109798_bb0040","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/j.1538-7836.2011.04433.x","article-title":"Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children","volume":"9","author":"Mitchell","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109798_bb0045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.blre.2018.06.003","article-title":"Are low-molecular-weight heparins safe and effective in children? A systematic review","volume":"33","author":"Klaassen","year":"2019","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.thromres.2026.109798_bb0050","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/sj.bjp.0707447","article-title":"Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children","volume":"153","author":"Nowak-G\u00f6ttl","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.thromres.2026.109798_bb0055","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1111\/jth.13856","article-title":"Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis","volume":"15","author":"Musgrave","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2026.109798_bb0060","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109798_bb0065","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol."},{"issue":"12","key":"10.1016\/j.thromres.2026.109798_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28688","article-title":"FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients","volume":"67","author":"Merino","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.thromres.2026.109798_bb0075","series-title":"Fragmin (dalteparin sodium). United States Prescribing Information. Pfizer Hospitals. Distributed by Pfizer Labs","first-page":"10001","year":"2024"},{"issue":"5","key":"10.1016\/j.thromres.2026.109798_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31638","article-title":"Fondaparinux approval in pediatrics: the story of my third child","volume":"72","author":"Young","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.thromres.2026.109798_bb0085","series-title":"Arixtra\u00ae(fondaparinux sodium), United States prescribing information","year":"2024"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:28:53Z","timestamp":1787675333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826002173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":17,"alternative-id":["S0049384826002173"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109798","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of fondaparinux in pediatric venous thromboembolism: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109798"}}